Group 1: Financial Performance - Hengyu Environmental reported a revenue of 294 million yuan for 2025, an increase of 89.87%, and a net profit of 35.93 million yuan, up 106.25% [1] - Zhongke Shuguang achieved a revenue of 14.97 billion yuan in 2025, growing by 13.86%, with a net profit of 2.113 billion yuan, reflecting a 10.54% increase [2] - Oat Technology's revenue reached 619 million yuan, marking a 24.33% growth, and a net profit of 137 million yuan, up 42.63% [4] - Yongxi Electronics reported a revenue of 4.4 billion yuan, a 21.92% increase, with a net profit of 82.24 million yuan, up 23.99% [5] Group 2: Shareholder Actions - Yashida Optoelectronics announced that a shareholder plans to reduce holdings by up to 1.6 million shares, representing no more than 0.976% of the total share capital [3] - Yuanli Co. intends to repurchase shares worth 50 to 60 million yuan for employee stock ownership plans, with a maximum repurchase price of 20 yuan per share [6] - Conch Cement's controlling shareholder plans to increase holdings by 700 million to 1.4 billion yuan [7] - Huaneng Hydropower's controlling shareholder plans to increase holdings by 100 to 150 million yuan [8] Group 3: Corporate Announcements - Baotai's drug application for Darpobatin injection has been accepted by the National Medical Products Administration [14] - Changchun High-tech's subsidiary received approval for clinical trials of GenSci141 ointment [15] - Tongwei Co. is planning to acquire 100% of Lihua Qingneng, with stock trading suspended for up to 10 trading days [16] - Guoyao Modern's application for the raw material drug Minaprine has been approved [20] Group 4: Market Activities - Kaipu Cloud announced the termination of the acquisition of Nanning Taike [21] - Boji Pharmaceutical plans to reduce its holdings by up to 0.69% of the total share capital [23] - ST Renfu intends to issue shares to its controlling shareholder to raise 3 to 3.5 billion yuan for innovative drug development projects [24] - Huayi Technology submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [25]

证券代码：605199 证券简称：ST葫芦娃 公告编号：2026-011 海南葫芦娃药业集团股份有限公司关于获得吸入用异丙托溴铵溶液药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督管理局（以下简称"国家 药监局"）核准签发的关于吸入用异丙托溴铵溶液《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：吸入用异丙托溴铵溶液 剂型：吸入制剂 注册分类：化学药品4类 规格：2ml：0.25mg（按C??H??BrNO?计）、2ml：0.5mg（按C??H??BrNO?计） 上市许可持有人：海南葫芦娃药业集团股份有限公司 受理号：CYHS2403031、CYHS2403032 药品批准文号：国药准字H20263362、国药准字H20263363 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。 二、药品研发及相关 2ml：0.25mg的吸入用异丙托溴铵溶液可与 ...

ST葫芦娃（605199）(605199.SH)发布公告，公司近日收到国家药品监督管理局(以下简称"国家药监局") 核准签发的关于吸入用异丙托溴铵溶液《药品注册证书》。上述药品获得《药品注册证书》，将进一步 丰富公司产品线，对公司的发展起到积极作用。 ...

智通财经APP讯，ST葫芦娃(605199.SH)发布公告，公司近日收到国家药品监督管理局(以下简称"国家药 监局")核准签发的关于吸入用异丙托溴铵溶液《药品注册证书》。上述药品获得《药品注册证书》，将 进一步丰富公司产品线，对公司的发展起到积极作用。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the inhalation solution of ipratropium bromide, which is indicated for the treatment of asthma and chronic obstructive pulmonary disease [1] Group 1: Product Approval - The approved specifications for the drug are 2ml: 0.25mg and 2ml: 0.5mg, which are considered equivalent to passing the consistency evaluation of generic drug quality and efficacy [1] - A total of 29 companies in China have been approved to produce this drug as of the announcement date [1] Group 2: Research and Development Investment - The company has invested a total of 5.9089 million yuan in the research and development of this product [1] Group 3: Market Uncertainty - The sales performance of the drug is subject to uncertainties influenced by policies and market factors [1]

ST葫芦娃2月24日公告，公司近日收到国家药品监督管理局核准签发的吸入用异丙托溴铵溶液《药品注 册证书》。2ml：0.25mg的吸入用异丙托溴铵溶液可与吸入性β-受体激动剂合用于治疗急性或慢性哮喘 引起的可逆性气道阻塞。2ml：0.5mg的吸入用异丙托溴铵溶液作为支气管扩张剂用于慢性阻塞性肺疾 病，包括慢性支气管炎和肺气肿，引起的支气管痉挛的维持治疗。该药品可与吸入性β受体激动剂合用 于治疗慢性阻塞性肺疾病，包括慢性支气管炎和哮喘，引起的急性支气管痉挛。公司对该产品已累计投 入研发费用590.89万元（未经审计）。 ...